Patient Capital Management LLC Has $49.19 Million Stake in Crocs, Inc. $CROX

Patient Capital Management LLC grew its position in Crocs, Inc. (NASDAQ:CROX) by 17.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 588,794 shares of the textile maker’s stock after purchasing an additional 85,416 shares during the quarter. Crocs makes up about 2.0% of Patient Capital Management LLC’s portfolio, making the stock its 26th largest position. Patient Capital Management LLC’s holdings in Crocs were worth $49,194,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Crocs by 159.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 746 shares of the textile maker’s stock valued at $79,000 after acquiring an additional 459 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Crocs by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 211,305 shares of the textile maker’s stock valued at $22,441,000 after purchasing an additional 8,331 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Crocs by 74.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 14,848 shares of the textile maker’s stock worth $1,594,000 after purchasing an additional 6,359 shares during the period. GAMMA Investing LLC increased its holdings in Crocs by 93.0% in the second quarter. GAMMA Investing LLC now owns 2,627 shares of the textile maker’s stock worth $266,000 after purchasing an additional 1,266 shares in the last quarter. Finally, Foster Victor Wealth Advisors LLC lifted its stake in Crocs by 4.9% in the second quarter. Foster Victor Wealth Advisors LLC now owns 101,700 shares of the textile maker’s stock valued at $10,653,000 after buying an additional 4,728 shares during the period. Institutional investors own 93.44% of the company’s stock.

Insider Activity at Crocs

In related news, Director John B. Replogle purchased 3,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were bought at an average price of $74.50 per share, with a total value of $223,500.00. Following the acquisition, the director owned 18,417 shares of the company’s stock, valued at $1,372,066.50. This trade represents a 19.46% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.72% of the company’s stock.

Crocs Trading Down 1.0%

Shares of Crocs stock opened at $82.27 on Wednesday. The company has a market capitalization of $4.27 billion, a P/E ratio of 26.80 and a beta of 1.54. The stock has a fifty day simple moving average of $85.29 and a 200 day simple moving average of $86.82. Crocs, Inc. has a 12-month low of $73.21 and a 12-month high of $122.84. The company has a current ratio of 1.40, a quick ratio of 0.83 and a debt-to-equity ratio of 0.97.

Crocs (NASDAQ:CROX) last posted its earnings results on Thursday, October 30th. The textile maker reported $2.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.56. The firm had revenue of $996.30 million during the quarter, compared to analyst estimates of $960.14 million. Crocs had a net margin of 4.48% and a return on equity of 43.14%. The business’s revenue was down 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.60 EPS. Crocs has set its Q4 2025 guidance at 1.820-1.92 EPS. On average, sell-side analysts anticipate that Crocs, Inc. will post 13.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CROX has been the topic of several research analyst reports. Monness Crespi & Hardt increased their target price on shares of Crocs from $92.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Zacks Research lowered shares of Crocs from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 30th. Bank of America decreased their target price on Crocs from $99.00 to $98.00 and set a “buy” rating for the company in a research report on Tuesday, October 21st. Baird R W lowered Crocs from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 7th. Finally, Wall Street Zen lowered Crocs from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Crocs presently has a consensus rating of “Hold” and an average price target of $99.25.

Crocs Company Profile

Crocs, Inc is a global footwear designer, developer and distributor best known for its lightweight, proprietary Croslite™ foam-clog construction. The company’s product portfolio encompasses a range of styles, including clogs, sandals, slides, boots and sneakers, all featuring the slip-resistant, odor-resistant and cushion-providing qualities of the Croslite material. Crocs distributes its products through an omnichannel network that includes e-commerce platforms, company-owned retail stores, authorized dealers and wholesale partners.

Founded in 2002 by Scott Seamans, Lyndon “Duke” Hanson and George Boedecker Jr., Crocs launched its first clog on the island of Vail, Colorado.